<div id="readability-page-1"><div> <p>(RTTNews) - Annovis Bio, Inc. (ANVS), a clinical-stage biotechnology firm that develops drugs to treat neurodegeneration, announces a public offering in which it intends to offer shares and accompanying warrants.</p> <p>Annovis Bio develops treatments for Alzheimer's disease (AD) and Parkinson's disease. The firm's lead drug candidate, Buntanetap (formerly posiphen), is an investigational once-daily oral therapy.</p> <p>Annovis intends to use the net proceeds from the offering for the continued clinical development of its lead compound Buntanetap in a Phase 3 study for Alzheimer's disease (AD), and for working capital and general corporate purposes.</p> <p>ANVS has traded between $1.54 and $5.50 over the last year. The stock closed Tuesday's trade at $1.94, down 5.37%.</p> <p>In the pre-market, ANVS is down 18.77% at $1.58.</p> <p>For more such news For More Such Biotech Stock News, visit rttnews.com. </p> <p>The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.</p> </div></div>

ANVS

<p>Annovis Bio, Inc. (ANVS) has announced a public offering of shares and warrants to fund the clinical development of its lead drug, Buntanetap, for Alzheimer's disease. The stock closed at $1.94, down 5.37%, and is down 18.77% in pre-market trading at $1.58.</p>

Annovis Bio Announces Offering Of Shares And Warrants To Advance Buntanetap In AD; Stock Down